Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 12/20 | 0.51 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16995121 | 0.94 | P2RX7 (0.47) | P2RX7DPP4ALDH1A1HPGDHTT | |
| SCHEMBL16995123 | 0.77 | P2RX7 (0.45) | P2RX7ALDH1A1HPGDHTT | |
| SCHEMBL18371703 | 0.75 | P2RX7 (0.51) | P2RX7 | |
| SCHEMBL15797541 | 0.71 | P2RX7 (0.54) | P2RX7DPP4 | |
| SCHEMBL17001525 | 0.71 | P2RX7 (0.48) | P2RX7DPP4SLC6A2SLC6A4 | |
| SCHEMBL16995086 | 0.70 | ALDH1A1 (0.48) | P2RX7ALDH1A1HPGDHTT | |
| SCHEMBL16461215 | 0.69 | DPP4 (0.56) | DPP4ALDH1A1HPGDSLC6A4 | |
| SCHEMBL15797371 | 0.69 | DPP4 (0.46) | P2RX7DPP4ALDH1A1SLC6A2 | |
| SCHEMBL17001577 | 0.69 | P2RX7 (0.51) | P2RX7DPP4 | |
| SCHEMBL12701048 | 0.68 | P2RX7 (0.50) | P2RX7DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10167281-B2 | Substituted thiazole or oxazole P2X7 receptor antagonists | AXXAM S.P.A. (IT) | 2019-01-01 | — | — | US | disclosed |
| EP-3102573-B1 | SUBSTITUTED THIAZOLE OR OXAZOLE P2X7 RECEPTOR ANTAGONISTS | AXXAM SPA (IT) | 2018-04-11 | — | — | EP | disclosed |
| US-20170283409-A1 | SUBSTITUTED THIAZOLE OR OXAZOLE P2X7 RECEPTOR ANTAGONISTS | AXXAM S.P.A. (IT) | 2017-10-05 | — | — | US | disclosed |
| US-20170283409-A1 | SUBSTITUTED THIAZOLE OR OXAZOLE P2X7 RECEPTOR ANTAGONISTS | AXXAM S.P.A. (IT) | 2017-10-05 | — | — | US | disclosed |
| US-9718812-B2 | Substituted thiazole or oxazole P2X7 receptor antagonists | AXXAM S.P.A. (IT) | 2017-08-01 | — | — | US | disclosed |
| US-9718812-B2 | Substituted thiazole or oxazole P2X7 receptor antagonists | AXXAM S.P.A. (IT) | 2017-08-01 | — | — | US | disclosed |
| US-20170008883-A1 | SUBSTITUTED THIAZOLE OR OXAZOLE P2X7 RECEPTOR ANTAGONISTS | AXXAM S.P.A. (IT) | 2017-01-12 | — | — | US | disclosed |
| US-20170008883-A1 | SUBSTITUTED THIAZOLE OR OXAZOLE P2X7 RECEPTOR ANTAGONISTS | AXXAM S.P.A. (IT) | 2017-01-12 | — | — | US | disclosed |
| EP-2905282-A1 | Substituted thiazole or oxazole as P2X7 receptor antagonists | AXXAM S.p.A. (IT) | 2015-08-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10167281-B2 | Substituted thiazole or oxazole P2X7 receptor antagonists | P2RX7, P2RX1, P2RX2 | P2RX7 1/4885DPP4 670/4885ALDH1A1 1516/4885 |
| US-20170283409-A1 | SUBSTITUTED THIAZOLE OR OXAZOLE P2X7 RECEPTOR ANTAGONISTS | P2RX7, P2RX1, P2RX2 | P2RX7 1/4885DPP4 670/4885ALDH1A1 1516/4885 |
| US-20170008883-A1 | SUBSTITUTED THIAZOLE OR OXAZOLE P2X7 RECEPTOR ANTAGONISTS | P2RX7, P2RX1, P2RX2 | P2RX7 1/4885DPP4 649/4885ALDH1A1 1523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.